|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Feasibility of Vis/NIR spectroscopy for detection of flaws in hazelnut kernels显示文摘 | Roberto Moscetti Ron P. Haff Ben Aernouts Wouter Saeys Danilo Monarca Massimo Cecchini Riccardo Massantini | 2013 | Journal of Food Engineering2013，，1： | 1 |
| 2 | Up-front chemotherapy and radiation treatment in newly diagnosed non-small-cell lung cancer with brain metastases: Survey by outcome research network for e- valuation of treatment results in oncology显示文摘 | Moscetti L Nelli F Felici A | 2007 | Cancer2007，109，2： | 1 |
| 3 | Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Padalino D | 2005 | J Chemother2005，17，6： | 1 |
| 4 | Nondestructive detection of insect infested chestnuts based on NIR spectroscopy显示文摘 | Moscetti R Haff R P Saranwong S | | 0，，： | 1 |
| 5 | Gemcitabine and cisplatin in the treatment of elderly patients with advanced non - small cell lung cancer: impact of comorbidities on safety and efficacy outcome 显示文摘 | Moscetti L Nelli F Padalino D | 2005 | J Cemother2005，17，6： | 1 |
| 6 | C, emeitabine and eisplatin in the treatment of elderly patients with advanced non-small cell lung cancer:impact of eomorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Padalino D | 2005 | Chemotherapy2005，17，6： | 1 |
| 7 | A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin显示文摘 | Moscetti L Padalino D Capomolla E | 2005 | J Exp Clin Cancer Res2005，24，1： | 1 |
| 8 | Up-tront chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: Survey by outcome research network for evaluation of treatment results in oncology 显示文摘 | Moscetti L Nelli F Felici A | 2007 | Cancer2007，109，2： | 1 |
| 9 | Post-epidemic chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period 显示文摘 | Sissoko D Malvy D Ezzedine K Renault P Moscetti F Ledrans M Pierre V | 2009 | PLoS Negl Trop Dis2009，3，3： | 1 |
| 10 | A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin显示文摘 | Moscetti L Padalino D Capomolla E | 2005 | J Exp Clin Cancer Res2005，24，1： | 1 |
| 11 | A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin显示文摘 | Moscetti L Padalino D Capomolla E | | 0，，01： | 1 |
| 12 | Gemcitabine and cisp latin in the treatment of elderly patients with advanced non small cell lung cancer:impact of comorbidities on safety and efficacyoutcome显示文摘 | Moscetti L Nelli F Padalino D | 2005 | J Chemother2005，17，6： | 1 |
| 13 | Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature显示文摘 | Moscetti L Saltarelli R Giuliani R | 2000 | Tumori2000，86，： | 1 |
| 14 | First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer显示文摘AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We designed a single-arm prospective, multicentre, open-label phase Ⅱ study to evaluate the combination of erlotinib (100 mg/d, orally) and weekly FDR-Gem (1000 mg/m 2 , infused at 10 mg/m 2 per minute) in a population of previously untreated patients with locally advanced, inoperable, or metastatic pancreatic cancer. Primary endpoint was the rate of progression-free survival at 6 mo (PFS-6); secondary endpoints were overall response rate (ORR), response duration, tolerability, overall survival (OS), and clinical benefit. Treatment was not considered to be of further interest if the PFS-6 was < 20% (p0 = 20%), while a PFS-6 > 40% would be of considerable interest (p1 = 40%); with a 5% rejection error (α = 5%) and a power of 80%, 35 fully evaluable patients with metastatic disease were required to be enrolled in order to complete the study. Analysis of prognostic factors for survival was also carried out. RESULTS: From May 2007 to September 2009, 46 patients were enrolled (male/female: 25/21; median age: 64 years; median baseline carbohydrate antigen 19-9 (CA 19-9): 897 U/mL; locally advanced/metastatic disease: 5/41). PFS-6 and median PFS were 30.4% and 14 wk (95%CI: 10-19), respectively; 1-year and median OS were 20.2% and 26 wk (95%CI: 8-43). Five patients achieved an objective response (ORR: 10.9%, 95%CI: 1.9-19.9); disease control rate was 56.5% (95%CI: 42.2-70.8); clinical benefit rate was 43.5% (95%CI: 29.1-57.8). CA 19-9 serum levels were decreased by > 25% as compared to baseline in 14/23 evaluable patients (63.6%). Treatment was well-tolerated, with skin rash being the most powerful predictor of both longer PFS (P < 0.0001) and OS (P = 0.01) at multivariate analysis (median OS for patients with or without rash: 42 wk vs 15 wk, respectively, Log-rank P = 0.03). Additional predictors of better outcome were: CA 19-9 reduction, female sex (for PFS), and good performance status (for OS). CONCLUSION: Primary study endpoint was not met. However, skin rash strongly predicted erlotinib efficacy, suggesting that a pharmacodynamic-based strategy for patient selection deserves further investigation. | Vanja Vaccaro Emilio Bria Isabella Sperduti Alain Gelibter Luca Moscetti Giovanni Mansueto Enzo Maria Ruggeri Teresa Gamucci Francesco Cognetti Michele Milella | 2013 | World Journal of Gastroenterology2013，19，28： | 1 |
| 15 | Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer:impact of comorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Padalino D | 2005 | J Chemother2005，17，6： | 1 |
| 16 | Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer, impact of comorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Padalino D | 2005 | J Chemother2005，17，6： | 1 |
| 17 | Gemcitabin and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer:impact of comorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Pannlino D | | 0，，06： | 1 |
| 18 | Gemicitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer:impact of comorbidities on safety and efficacy outcome显示文摘 | Moscetti L Nelli F Panalino D | 2005 | J Chemother2005，17，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员